Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
Mar 2019
Historique:
entrez: 22 3 2019
pubmed: 22 3 2019
medline: 10 4 2019
Statut: ppublish

Résumé

The prevalence of anastomotic recurrence (AR) in colorectal cancer (CRC) after resection of the primary tumor (PT) is 5% to 14%. However, no association has been observed between specific somatic genetic alterations and AR. Such associations may shed light on the mechanism of AR. We experienced 2 patients with AR of CRC. The first patient was a 42-year-old woman who underwent resection of an AR of rectal cancer 2 times within 19 months after resection of the PT. The second patient was a 77-year-old woman who underwent resection of an AR of ascending colon cancer twice within 38 months after resection of the PT. Both cases were diagnosed as repetitive AR. Loss of heterozygosity analysis, microsatellite instability (MSI) study of 9 microsatellite loci, and mutational analysis of KRAS, BRAF, APC, TP53, and SMAD4 were performed. All the lesions, except 1, harbored mutations in APC, KRAS, and TP53, without MSI, after neoadjuvant chemoradiotherapy. The APC, KRAS, and TP53 mutations were pathogenic or likely pathogenic in the PTs and ARs. Both women harbored the same KRAS G13D mutation, which accounts for 8% of all KRAS mutations in sporadic CRC s. The probability of the incidental occurrence of KRAS G13D mutations in both cases is 0.64%, provided that the mutations were independent of AR. Our findings may shed light on the mechanism of AR in CRC, namely, that the PT harbored the same mutations as the AR and the lesions in both cases harbored the KRAS G13D mutation.

Identifiants

pubmed: 30896620
doi: 10.1097/MD.0000000000014781
pii: 00005792-201903220-00009
pmc: PMC6709076
doi:

Substances chimiques

APC protein, human 0
Adenomatous Polyposis Coli Protein 0
KRAS protein, human 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14781

Références

Indian J Surg. 2015 Jun;77(3):232-6
pubmed: 26246708
Oncotarget. 2017 Jun 27;8(26):42487-42494
pubmed: 28476018
Colorectal Dis. 2009 Jan;11(1):60-6
pubmed: 18462223
J Am Coll Surg. 2002 Jul;195(1):33-40
pubmed: 12113543
J Surg Oncol. 2016 Aug;114(2):228-36
pubmed: 27158137
JAMA Surg. 2015 Aug;150(8):722-9
pubmed: 26038887
N Engl J Med. 2009 Apr 2;360(14):1408-17
pubmed: 19339720
Dis Colon Rectum. 2005 May;48(5):897-909
pubmed: 15785892
J Clin Oncol. 2012 Jun 20;30(18):2256-64
pubmed: 22547595
JAMA. 2010 Oct 27;304(16):1812-20
pubmed: 20978259
Cancer. 2016 Sep 1;122(17):2698-707
pubmed: 27244540
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011
J Clin Oncol. 2012 Oct 10;30(29):3570-7
pubmed: 22734028
Nat Rev Clin Oncol. 2009 Sep;6(9):519-27
pubmed: 19636327
N Engl J Med. 2001 Apr 19;344(16):1196-206
pubmed: 11309634
Cell. 2009 Dec 24;139(7):1315-26
pubmed: 20064377

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH